Green Thumb Industries (GTBIF) Cash from Financing Activities (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Cash from Financing Activities came in at $5.7 million in Q1 2026, up 219.97% YoY from $1.8 million in Q1 2025, and up 127.02% on a QoQ basis from -$21.1 million in Q4 2025.
Green Thumb Industries (GTBIF) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Cash from Financing Activities data on file, last reported at $5.7 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 219.97% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.5 million (up 54.46% YoY) and the FY2025 annual result came in at -$50.9 million, up 46.71% from the prior year.
- Cash from Financing Activities improved to $5.7 million in Q1 2026, from -$21.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $18.9 million in Q4 2022 to a low of -$51.1 million in Q3 2024.
- A 5-year average of -$8.5 million and a median of -$5.8 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 10420.0% — and 2024, when it slumped 8320.59%.
- Tracing GTBIF's Cash from Financing Activities over 5 years: stood at $18.9 million in 2022, then plunged by 130.97% to -$5.8 million in 2023, then tumbled by 57.38% to -$9.2 million in 2024, then plunged by 129.8% to -$21.1 million in 2025, then surged by 127.02% to $5.7 million in 2026.
- The last three Cash from Financing Activities figures came in at $5.7 million (Q1 2026), -$21.1 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Green Thumb Industries | 1.65 Bn | 1.37 Bn | 137.87 Mn | -57.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.66 Mn |
| Jun 30, 2026 | -57.66 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Mar 31, 2026 | 5.71 Mn |
| Dec 31, 2025 | -21.12 Mn |
| Dec 31, 2025 | -21.12 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Jun 30, 2025 | -22.43 Mn |
| Jun 30, 2025 | -22.43 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -51.06 Mn |
| Sep 30, 2024 | -51.06 Mn |
| Jun 30, 2024 | -23.89 Mn |
| Jun 30, 2024 | -23.89 Mn |
| Mar 31, 2024 | -11.45 Mn |
| Mar 31, 2024 | -11.45 Mn |